<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36597543</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Dec</Month><Day>23</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2022.12.21.22283753</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2022.12.21.22283753</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Long Covid is an emerging chronic illness potentially affecting millions, sometimes preventing the ability to work or participate in normal daily activities. COVID-OUT was an investigator-initiated, multi-site, phase 3, randomized, quadruple-blinded placebo-controlled clinical trial (NCT04510194). The design simultaneously assessed three oral medications (metformin, ivermectin, fluvoxamine) using two by three parallel treatment factorial assignment to efficiently share placebo controls and assessed Long Covid outcomes for 10 months to understand whether early outpatient treatment of SARS-CoV-2 with metformin, ivermectin, or fluvoxamine prevents Long Covid.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This was a decentralized, remotely delivered trial in the US of 1,125 adults age 30 to 85 with overweight or obesity, fewer than 7 days of symptoms, and enrolled within three days of a documented SARS-CoV-2 infection. Immediate release metformin titrated over 6 days to 1,500mg per day 14 days total; ivermectin 430mcg/kg/day for 3 days; fluvoxamine, 50mg on day one then 50mg twice daily through 14 days. Medical-provider diagnosis of Long Covid, reported by participant by day 300 after randomization was a pre-specified secondary outcome; the primary outcome of the trial was severe Covid by day 14.</AbstractText><AbstractText Label="RESULT" NlmCategory="UNASSIGNED">The median age was 45 years (IQR 37 to 54), 56% female of whom 7% were pregnant. Two percent identified as Native American; 3.7% as Asian; 7.4% as Black/African American; 82.8% as white; and 12.7% as Hispanic/Latino. The median BMI was 29.8 kg/m<sup>2</sup> (IQR 27 to 34); 51% had a BMI &gt;30kg/m<sup>2</sup>. Overall, 8.4% reported having received a diagnosis of Long Covid from a medical provider: 6.3% in the metformin group and 10.6% in the metformin control; 8.0% in the ivermectin group and 8.1% in the ivermectin control; and 10.1% in the fluvoxamine group and 7.5% in the fluvoxamine control. The Hazard Ratio (HR) for Long Covid in the metformin group versus control was 0.58 (95% CI 0.38 to 0.88); 0.99 (95% CI 0.592 to 1.643) in the ivermectin group; and 1.36 in the fluvoxamine group (95% CI 0.785 to 2.385).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">There was a 42% relative decrease in the incidence of Long Covid in the metformin group compared to its blinded control in a secondary outcome of this randomized phase 3 trial.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bramante</LastName><ForeName>Carolyn T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buse</LastName><ForeName>John B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Endocrinology, University of North Carolina, Chapel Hill, ND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebovitz</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>General Internal Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicklas</LastName><ForeName>Jacinda</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Colorado, Denver, CO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puskarich</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Emergency Medicine, Hennepin County Medical Center, Minneapolis, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>UnitedHealth Group, Optum Labs, Minnetonka, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belani</LastName><ForeName>Hrishikesh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine, Olive View - University of California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Blake</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Atlanta Veterans Affairs Medical Center, Atlanta, Georgia; Department of Medicine, Emory University School of Medicine, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huling</LastName><ForeName>Jared D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tignanelli</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgery, Medical School, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pullen</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases, University of Minnesota Medical School, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>Lianne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proper</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odde</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klatt</LastName><ForeName>Nichole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Surgery, Medical School, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherwood</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindberg</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wirtz</LastName><ForeName>Esteban Lemus</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karger</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckman</LastName><ForeName>Kenny</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erickson</LastName><ForeName>Spencer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenno</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>Katrina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Barkha</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffiths</LastName><ForeName>Gwendolyn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhat</LastName><ForeName>Neeta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulware</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Infectious Diseases, University of Minnesota Medical School, Minneapolis, MN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 DK124654</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002489</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 HL133604</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA210190</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK124723</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR002492</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA254849</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>1</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36597543</ArticleId><ArticleId IdType="pmc">PMC9810227</ArticleId><ArticleId IdType="doi">10.1101/2022.12.21.22283753</ArticleId><ArticleId IdType="pii">2022.12.21.22283753</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC. Post-Covid Conditions: Information for Healthcare Providers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html. Published 2022.
Accessed 11 Dec, 2022.</Citation></Reference><Reference><Citation>Yang C, Zhao H, Tebbutt SJ. A glimpse into long COVID and symptoms. The Lancet Respiratory medicine. 2022;10(9):e81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9187332</ArticleId><ArticleId IdType="pubmed">35697054</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM. The Costs of Long COVID. JAMA Health Forum. 2022;3(5):e221809.</Citation><ArticleIdList><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and Correlates of Long COVID Symptoms Among US Adults. JAMA Netw Open. 2022;5(10):e2238804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet (London, England). 2022;400(10350):452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Rando HM, Bennett TD, Byrd JB, et al. Challenges in defining Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported information. medRxiv. 2021;doi:10.1101/2021.1103.1120.21253896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.1103.1120.21253896</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff ER, Girvin AT, Bennett TD, et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet Digit Health. 2022;4(7):e532&#x2013;e541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110014</ArticleId><ArticleId IdType="pubmed">35589549</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath LJ, Scott AM, Surinach A, Chambers R, Benigno M, Malhotra D. Use of the Postacute Sequelae of COVID-19 Diagnosis Code in Routine Clinical Practice in the US. JAMA network open. 2022;5(10):e2235089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9539719</ArticleId><ArticleId IdType="pubmed">36201207</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff ER, Girvin AT, Bennett TD, et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data. The Lancet Digital Health. 2022;4(7):e532&#x2013;e541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110014</ArticleId><ArticleId IdType="pubmed">35589549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. New England Journal of Medicine. 2022;387(7):599&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191&#x2013;2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Molloy SF, White IR, Nunn AJ, Hayes R, Wang D, Harrison TS. Multiplicity adjustments in parallel-group multi-arm trials sharing a control group: Clear guidance is needed. Contemp Clin Trials. 2022;113:106656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8844584</ArticleId><ArticleId IdType="pubmed">34906747</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker RA, Weir CJ. Non-adjustment for multiple testing in multi-arm trials of distinct treatments: Rationale and justification. Clin Trials. 2020;17(5):562&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534018</ArticleId><ArticleId IdType="pubmed">32666813</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson JE, Cook NR, Lee I-M, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. New England Journal of Medicine. 2018;380(1):33&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425757</ArticleId><ArticleId IdType="pubmed">30415629</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson JE, Cook NR, Lee IM, et al. Marine n&#x2013;3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. New England Journal of Medicine. 2018;380(1):23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6392053</ArticleId><ArticleId IdType="pubmed">30415637</ArticleId></ArticleIdList></Reference><Reference><Citation>Declercq J, Van Damme KFA, De Leeuw E, et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respir Med. 2021;9(12):1427&#x2013;1438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8555973</ArticleId><ArticleId IdType="pubmed">34756178</ArticleId></ArticleIdList></Reference><Reference><Citation>Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. New England Journal of Medicine. 2022;387(24):e65.</Citation><ArticleIdList><ArticleId IdType="pubmed">36516099</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ, Stone GW. The Primary Outcome Fails &#x2014; What Next? New England Journal of Medicine. 2016;375(9):861&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">27579636</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett ML, Sax PE. Long-term Follow-up After Critical COVID-19: REMAP-CAP Revisited. JAMA. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">36525259</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee for the REMAP-CAP Investigators. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial2022. Located at: JAMA.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9857594</ArticleId><ArticleId IdType="pubmed">36525245</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Morrone MC, Patrono C, et al. Long Covid: where we stand and challenges ahead. Cell Death Differ. 2022;29(10):1891&#x2013;1900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle BT, Dock C, Hemmat M, et al. Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets. bioRxiv. 2020:2020.2005.2022.111237.</Citation></Reference><Reference><Citation>Karam BS, Morris RS, Bramante CT, et al. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses. Journal of medical virology. 2021;93(4):1843&#x2013;1846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8159020</ArticleId><ArticleId IdType="pubmed">33314219</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthasarathy H, Tandel D, Siddiqui AH, Harshan KH. Metformin suppresses SARS-CoV-2 in cell culture. Virus research. 2022;323:199010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9676078</ArticleId><ArticleId IdType="pubmed">36417940</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller MA, Sharma Y, Dupee Z, et al. Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses. JCI Insight. 2021;6(18).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492301</ArticleId><ArticleId IdType="pubmed">34357881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura-L&#xf3;pez C, Cervantes-Luevano K, Aguirre-S&#xe1;nchez JS, et al. Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial. Biomed Pharmacother. 2022;152:113223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9159967</ArticleId><ArticleId IdType="pubmed">35709650</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Liu Y, Huang Z, et al. SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ. 2022;29(6):1240&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9177730</ArticleId><ArticleId IdType="pubmed">34997207</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Han Y, Yang L, et al. SARS-CoV-2 Infection Causes Dopaminergic Neuron Senescence. Res Sq. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10843182</ArticleId><ArticleId IdType="pubmed">38237586</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668&#x2013;2675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4427053</ArticleId><ArticleId IdType="pubmed">25536258</ArticleId></ArticleIdList></Reference><Reference><Citation>Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;2010(4):CD002967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7138050</ArticleId><ArticleId IdType="pubmed">20393934</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquel FJ, Umpierrez GE. Web Exclusive. Annals for Hospitalists Inpatient Notes - How We Treat Hyperglycemia in the Hospital. Annals of internal medicine. 2021;174(8):Ho2&#x2013;ho4.</Citation><ArticleIdList><ArticleId IdType="pubmed">34399081</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LL, Umpierrez GE, Inzucchi SE. Management of Hyperglycemia in Hospitalized, Non-Critically Ill Adults. The New England journal of medicine. 2022;387(11):1040&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">36103419</ArticleId></ArticleIdList></Reference><Reference><Citation>Haltmeier T, Benjamin E, Beale E, Inaba K, Demetriades D. Insulin-Treated Patients with Diabetes Mellitus Undergoing Emergency Abdominal Surgery Have Worse Outcomes than Patients Treated with Oral Agents. World J Surg. 2016;40(7):1575&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pubmed">26913730</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz KM, Marroquin OC, Zenati MS, et al. Association Between Preoperative Metformin Exposure and Postoperative Outcomes in Adults With Type 2 Diabetes. JAMA Surg. 2020;155(6):e200416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7142798</ArticleId><ArticleId IdType="pubmed">32267474</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalafat E, Sukur YE, Abdi A, Thilaganathan B, Khalil A. Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. Ultrasound Obstet Gynecol. 2018;52(6):706&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">29749110</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyer S, Balani J, Shehata H. Metformin in Pregnancy: Mechanisms and Clinical Applications. Int J Mol Sci. 2018;19(7).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6073429</ArticleId><ArticleId IdType="pubmed">29973490</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand KMG, Saarelainen L, Sonajalg J, et al. Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study. BMJ Open Diabetes Res Care. 2022;10(1):e002363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8734020</ArticleId><ArticleId IdType="pubmed">34987051</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosey CM, Halpin K, Yan Y. Considering metformin as a second-line treatment for children and adolescents with prediabetes. Journal of pediatric endocrinology &amp; metabolism : JPEM. 2022;35(6):727&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">35503504</ArticleId></ArticleIdList></Reference><Reference><Citation>Masarwa R, Brunetti VC, Aloe S, Henderson M, Platt RW, Filion KB. Efficacy and Safety of Metformin for Obesity: A Systematic Review. Pediatrics. 2021;147(3).</Citation><ArticleIdList><ArticleId IdType="pubmed">33608415</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnakulasuriya LS, Fernando MMA, Adikaram AVN, et al. Metformin in the Management of Childhood Obesity: A Randomized Control Trial. Child Obes. 2018;14(8):553&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">30070925</ArticleId></ArticleIdList></Reference><Reference><Citation>Census. https://www.census.gov/quickfacts/fact/table/US/PST045221. Accessed.</Citation></Reference><Reference><Citation>Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. Annals of internal medicine. 2020;173(8):623&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384270</ArticleId><ArticleId IdType="pubmed">32673060</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>